John E Davis, the Chief Commercial Officer of $AORT, sold 6,563 shares of the company on 11-13-2025 for an estimated $300,966. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.2% of their shares of this class of stock. Following this trade, they now own 198,842 shares of this class of $AORT stock.
$AORT Insider Trading Activity
$AORT insiders have traded $AORT stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.
Here’s a breakdown of recent trading of $AORT stock by insiders over the last 6 months:
- JAMES P MACKIN (President & CEO) has made 0 purchases and 3 sales selling 64,290 shares for an estimated $2,882,191.
- JEAN F HOLLOWAY (SVP, General Counsel) has made 0 purchases and 8 sales selling 70,751 shares for an estimated $2,847,915.
- MARSHALL S. STANTON (SVP, Clinical & MD Affair) has made 0 purchases and 9 sales selling 66,891 shares for an estimated $2,330,311.
- JOHN E DAVIS (Chief Commercial Officer) has made 0 purchases and 3 sales selling 20,738 shares for an estimated $923,221.
- AMY HORTON (VP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 9,781 shares for an estimated $387,435.
- ANTHONY B. SEMEDO sold 2,600 shares for an estimated $74,027
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AORT Hedge Fund Activity
We have seen 118 institutional investors add shares of $AORT stock to their portfolio, and 84 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FRED ALGER MANAGEMENT, LLC added 1,230,155 shares (+1018.3%) to their portfolio in Q2 2025, for an estimated $38,257,820
- FMR LLC added 700,131 shares (+30.6%) to their portfolio in Q3 2025, for an estimated $29,643,546
- LOOMIS SAYLES & CO L P added 622,202 shares (+inf%) to their portfolio in Q3 2025, for an estimated $26,344,032
- MACQUARIE GROUP LTD removed 472,724 shares (-16.0%) from their portfolio in Q3 2025, for an estimated $20,015,134
- CHAMPLAIN INVESTMENT PARTNERS, LLC added 423,053 shares (+inf%) to their portfolio in Q3 2025, for an estimated $17,912,064
- OPHIR ASSET MANAGEMENT PTY LTD removed 380,242 shares (-38.0%) from their portfolio in Q2 2025, for an estimated $11,825,526
- TWO SIGMA INVESTMENTS, LP added 313,446 shares (+235.5%) to their portfolio in Q3 2025, for an estimated $13,271,303
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AORT Analyst Ratings
Wall Street analysts have issued reports on $AORT in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 11/07/2025
- Citizens issued a "Market Outperform" rating on 11/07/2025
- Canaccord Genuity issued a "Buy" rating on 11/07/2025
- JMP Securities issued a "Market Outperform" rating on 10/10/2025
- Stifel issued a "Buy" rating on 09/29/2025
To track analyst ratings and price targets for $AORT, check out Quiver Quantitative's $AORT forecast page.
$AORT Price Targets
Multiple analysts have issued price targets for $AORT recently. We have seen 6 analysts offer price targets for $AORT in the last 6 months, with a median target of $49.0.
Here are some recent targets:
- Daniel Stauder from Citizens set a target price of $53.0 on 11/07/2025
- Mike Matson from Needham set a target price of $58.0 on 11/07/2025
- William Plovanic from Canaccord Genuity set a target price of $51.0 on 11/07/2025
- Daniel Stauder from JMP Securities set a target price of $47.0 on 10/10/2025
- Rick Wise from Stifel set a target price of $46.0 on 09/29/2025
- Jeff Cohen from Ladenburg Thalmann set a target price of $38.8 on 08/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
